The collaboration between SciSparc and Clearmind continues to yield positive results in its obesity and metabolic disorder program

View post:
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial

The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program

Go here to see the original:
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in one upcoming investor conference in December.

Go here to read the rest:
Allogene Therapeutics Announces Participation in December Investor Conference

MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.

Original post:
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

PALO ALTO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced monthly revenue in November 2023 and provided certain preliminary unaudited financial results for gross and net sales for the one month ended November 2023 and year-to-date through November 30, 2023.

Continued here:
Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales...

NRTX-1001 investigational treatment has been well tolerated in all initial subjects

Continue reading here:
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant...

Virender Ahluwalia will serve as Interim Chief Financial Officer Virender Ahluwalia will serve as Interim Chief Financial Officer

Go here to see the original:
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO

Nicox SA Société anonyme with a registered capital of € 50,170,498

Read this article:
Number of voting rights as of November 30, 2023

Regulated Information

Original post:
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

SEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the publication in Blood of an abstract providing initial clinical data from the first patient treated at the lowest dose in the ongoing ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy. SC291 appeared safe and well tolerated, evaded immune detection, and induced a partial response in a patient with chronic lymphocytic leukemia (CLL). ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin lymphoma. Treatment in this dose escalation study is ongoing, and the company expects to present more data from this study at a later date in an appropriate venue.

See the rest here:
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of...

SHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (the “Proposal”) to acquire 100% of the equity of LianBio. According to the Schedule 13D filed on November 30, 2023 with the U.S. Securities and Exchange Commission (“SEC”) disclosing the Proposal, Tang Capital1 is currently approximately an 8.6% shareholder of LianBio.

View original post here:
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

Meeting adjourned to December 15, 2023 at 10 a.m. MT

Read the rest here:
Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders

SHANGHAI, China, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (TGA) has accepted the New Chemical Entity (NCE) application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC.

Read this article:
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA

Hyloris announces US FDA approval for Podofilox Gel

The rest is here:
Hyloris announces US FDA approval for Podofilox Gel

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Visit link:
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

See the original post:
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China

– Roche to acquire Carmot for an upfront payment of $2.7 billion and the potential for $400 million in milestone payments –

See the article here:
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche

Basel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

Read the original post:
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in...

Press Release

Excerpt from:
Mendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023 on December 14, 2023

Press release – No. 16 / 2023

Go here to read the rest:
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5